Cargando…
Immunological evaluation of peptide vaccination for cancer patients with the HLA ‐A11(+) or ‐A33(+) allele
The HLA‐A11 or ‐A33 allele is found in approximately 18% or 10% of the Asian population, respectively, but each of which is a minor allele worldwide, and therefore no clinical trials were previously conducted. To develop a therapeutic peptide vaccine for each of them, we investigated immunological r...
Autores principales: | Sakamoto, Shinjiro, Matsueda, Satoko, Takamori, Shinzo, Toh, Uhi, Noguchi, Masanori, Yutani, Shigeru, Yamada, Akira, Shichijo, Shigeki, Yamada, Teppei, Suekane, Shigetaka, Kawano, Kouichiro, Naitou, Masayasu, Sasada, Tetsuro, Hattori, Noboru, Kohno, Nobuoki, Itoh, Kyogo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5406587/ https://www.ncbi.nlm.nih.gov/pubmed/28178396 http://dx.doi.org/10.1111/cas.13189 |
Ejemplares similares
-
Immunological evaluation of peptide vaccination for cancer patients with the HLA-A26 allele
por: Sakamoto, Shinjiro, et al.
Publicado: (2015) -
Identification of biomarkers for personalized peptide vaccination in 2,588 cancer patients
por: Suekane, Shigetaka, et al.
Publicado: (2020) -
Evaluation of prognostic significance of granulocyte-related factors in cancer patients undergoing personalized peptide vaccination
por: Sakamoto, Shinjiro, et al.
Publicado: (2015) -
Immune responses of patients without cancer recurrence after a cancer vaccine over a long term
por: Suekane, Shigetaka, et al.
Publicado: (2022) -
A randomized phase II trial of personalized peptide vaccine with low dose cyclophosphamide in biliary tract cancer
por: Shirahama, Takahisa, et al.
Publicado: (2017)